TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
IKT

Inhibikase Therapeutics Inc

Healthcare · Biotechnology

2.30$ -0.4% vs. previous close Closing price · As of: Sep 17, 2026

Filings

Filings

Listed US companies must report material events to the Securities and Exchange Commission. This page lists the filings of Inhibikase Therapeutics Inc (IKT) with date, type and a link to the original document.

Filings IKT
Date Type Filing Original
09/08/2026 Current report (8-K) Inhibikase Therapeutics, Inc. (IKT): Regulation FD Disclosure; Financial Statements and Exhibits View report ↗
08/26/2026 Current report (8-K) Inhibikase Therapeutics, Inc. (IKT): Changes in Registrant's Certifying Accountant; Financial Statements and Exhibits View report ↗
08/11/2026 Current report (8-K) Inhibikase Therapeutics, Inc. (IKT): Results of Operations and Financial Condition; Financial Statements and Exhibits View report ↗
07/29/2026 Current report (8-K) Inhibikase Therapeutics, Inc. (IKT): Unregistered Sales of Equity Securities; Financial Statements and Exhibits View report ↗
07/23/2026 Current report (8-K) Inhibikase Therapeutics, Inc. (IKT): Regulation FD Disclosure; Financial Statements and Exhibits View report ↗
07/14/2026 Current report (8-K) Inhibikase Therapeutics, Inc. (IKT): Other Events; Financial Statements and Exhibits View report ↗

Showing the 100 most recent filings of the selected type.

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Filings: SEC EDGAR

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?